Study of BMS-986528 for Refractory Rheumatoid Arthritis
This study is testing a drug called BMS-986528 in people with rheumatoid arthritis (RA) that is difficult to treat. The main goals are to understand how safe BMS-986528 is and how well your body handles it. Researchers will also look for early signs that the drug might help improve RA. You could join if you are an adult between 18 and 65 years old with difficult-to-treat RA. The study aims to enroll 84 participants. The current recruitment status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 84 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for safety events for up to 54 weeks after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
At a glance
Conditions
Where it's being run
39 sites across 30 statesStudy leadership
- Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Number of participants with treatment-emergent adverse events (TEAEs)Up to Week 54
- Number of participants with Serious Adverse Events (SAEs)Up to Week 54